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Abstract
The multidomain HIV-1 Vif protein recruits several cellular partners to achieve neu-
tralization of the antiviral activity of APOBEC3 proteins. Vif neutralizes APOBEC-
3G and APOBEC3F predominantly by forming an E3 ubiquitin ligase with Cullin5,
ElonginB and ElonginC that targets these proteins for degradation by the ubiquitin-
protea-some pathway. Vif associates with the Cullin5-ElonginB-ElonginC complex by
binding directly to ElonginC via its SOCS-box motif and to Cullin5 via hydrophobic
residues within a zinc-binding region formed by a conserved HCCH motif. The HIV-1
Vif-Cullin5-ElonginBC complex is then able to ubiquitinate the APOBEC3G factor
bound to Vif by its N-terminal domain. In this review, we summarize the current
knowledge about the structural determinants of Vif that allow it to interact with
cellular and viral partners.
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I Introduction
The Human immunodeficiency virus (HIV) belongs to the Retroviridae family and,
in contrast with simple retroviruses, it encodes for several proteins in addition to the
three viral genes gag, pol and env, which constitute their structural and enzymatic
repertoire. These proteins are usually subdivided into regulatory proteins such as
Tat, Rev, and Nef, and auxiliary proteins including Vif (Virion Infectivity Factor),
Vpr and Vpu. The HIV auxiliary genes, initially thought to be dispensable for viral
replication, are now known to function as crucial enhancers of viral pathogenesis.
Vif, Vpr and Vpu act as versatile adaptors that connect viral and cellular pathways,
and lead to efficient viral replication, assembly and release (for a review, see [1]).
HIV-1 Vif is a cytoplasmic, 23 kDa protein, expressed late in the viral cycle and has
been known for a long time to be essential for viral replication. Vif is required in
nonpermissive cells but is dispensable for replication in permissive cell lines [2-5]. In
non-permissive cells, Vif-defective viruses (HIV-1∆vif) can produce virions, but they
fail to complete reverse transcription and cannot successfully infect new cells [6,7].
It took almost 20 years to identify the function of Vif [8,9]. It actually counteracts
the antiviral activity of recently identified members of the cellular cytidine deaminase
family, APOBEC3B, APOBEC3F and APOBEC3G (for a review see [10]). In the
absence of Vif, APOBEC3G is packaged into virions as a stable complex with the
viral core [11,12]. This provokes the deamination of cytidine to uracil during the
subsequent round of viral replication, leading to the production of non-functional
proviruses. Vif interacts with and adapts APOBEC3G to an ElonginB-ElonginC-
Cullin5 E3 ligase complex [13]. The bound APOBEC3G is then ubiquitinated and
degraded by the proteasome, allowing viral replication. It has also been proposed
that Vif can be down regulated APOBEC3G at the translational level [14-16].
Recent work suggest that DNA editing is not always necessary for antiviral activity
and that APOBEC3G and APOBEC3F may exert their antiviral activity by other
mechanisms than cytidine deamination [17,18]. To understand the function of a
given protein at the molecular level, an appreciation of functional domains, motifs,
and residues can be of tremendous help. With this aim, this review describes the
general biochemical properties of Vif and then its interactions with cellular and viral
partners from a structural point of view.
II General Biochemical Properties of VIF and Defini-
tion of its Different Domains
To date, little structural data is available on HIV-1 Vif protein and, more importantly
no three-dimensional structure exists. This lack of data is first due to the difficulty
of expressing high levels of soluble recombinant protein using either prokaryotic or
baculovirus expression systems. Vif is a highly basic protein (pI = 10.7) that is
conserved in all lentiviruses, except Equine Infectious Anemia Virus [19]. The Vif
proteins of closely related HIV-1 strains are highly conserved (e.g. 91% of identity
between HIV-1 HXB2 and HIV- 1 MN isolates), while those of slightly more distantly
related lentiviruses have diverged significantly (e.g. there is a maximum of 30% of
identity between HIV-1 HXB2 and SIV isolates) [20]. Alignments of Vif sequences
from HIV-1, HIV-2, and SIV subtypes (Fig. 1) highlight several highly conserved
motifs, i.e. an N-terminal tryptophan-rich stretch, a conserved HCCH motif and a
SOCS-box motif. The N-terminal tryptophan-rich stretch (residues 1 to 21) is highly
conserved (Fig. 1). Interestingly, different tryptophans (Fig. 2a) are required to me-
diate the Vif recognition and suppression of the target molecules APOBEC3G and
APOBEC3F [21]. This point will be discussed in section III. Amino acids 63-70 and
86-89 that are well conserved and predicted to be important for formation of β-strand
structures (Fig. 1) are critical for maintaining a normal expression level of Vif and
for viral infectivity [22]. In HIV-1, the conserved glutamic acid at position 88 and
the tryptophan at position 89 are located within the charged central hydrophilic re-
gion 88EWRKKR93 that is thought to enhance steady-state expression of Vif in host
cells [22]. The HCCH motif (residues 108-139) consists of two conserved His/Cys
pairs flanking a predicted α-helix that contains a cluster of hydrophobic conserved
residues (Figs. 1,2). This motif was shown to coordinate one Zn2+ ion through the
universally conserved residues H108, C114, C133 and H139, and to bind directly to
Cullin5 [23,24] (see section IV). The highly conserved 144SLQYLA149 motif [20] de-
fines the so-called BC-box motif and is crucial for inactivation of APOBEC3 proteins
[13]. This BC-box motif is responsible for the binding to ElonginC, which further
targets APOBEC3 antiviral factors to the proteasome. There are high similarities
between the conserved SLQ(Y/F)LA ΦΦΦΦ motif (Φ for hydrophobic residue) of Vif
and the SOCS-box of SOCS protein (suppressor of cytokine signalling). This subject
will be developed in section V and for purpose of clarity, this domain will be called
SOCS-box. Vif is a component of cytoplasmic RNPs mediating viral RNA interac-
tions with the Pr55Gag precursor and cellular factors [25-27] and Vif binds HIV-1
genomic RNA in vivo [25,27] and in vitro [25,28]. In addition, any mutation reducing
the affinity of Vif for RNA diminishes viral replication in non-permissive cell lines,
suggesting that RNA also plays a central role in Vif function [26,27]. This point will
be issued in section VI. Vif is subject to intravirion processing by the HIV-1 protease
[29]. Importantly, mutations in Vif that affect Pr-dependent processing also affect
the ability of Vif to regulate viral infectivity, suggesting that intravirion processing
of Vif is functionally relevant [29]. The processing site is located after L150 dow-
stream the highly conserved SOCS-box (Fig. 2b). The authors suggest that the Vif
processing site is defined by structural constraints rather than by a specific amino
acid sequence [30]. Post-translational phosphorylation of viral proteins by cellular
kinases regulates HIV-1 infectivity. Many viral proteins are regulated by phospho-
rylation at different stages of the virus life cycle. Vif is phosphorylated in vitro and
in vivo by cellular kinases and Vif phosphorylation is important for HIV-1 replica-
tion [31,32]. Four major phosphorylation sites were identified: T96, S144, T155 and
T188, the three latter within the C-terminal domain of Vif (Fig. 2a). Importantly,
T96 and S144 are highly conserved in all lentiviruses. Mutations of T96 resulted in
significant loss of Vif activity and inhibition of HIV-1 replication [32]. Mutation of
S144 to alanine resulted in loss of Vif activity, suggesting that phosphorylation at
this site plays an important role in regulating HIV-1 replication and infectivity [31].
Synthetic Vif peptides corresponding to the local sequences of the phosphorylation
sites were not phosphorylated by MAPK, suggesting that recognition of these sites
by MAPK is likely to require structural determinants outside the phosphorylation
sites [32]. Like several other proteins encoded by HIV-1, Vif proteins possess a strong
tendency toward self-association. In relatively native conditions, Vif proteins form
multimers in vitro, including dimers, trimers and tetramers [33]. This propensity for
self association, from dimers to tetramers, has been also observed in cross-linking
experiments [34]. This behavior was not limited to in vitro studies, as experiments
based on co-immunoprecipitation or two-hybrid systems revealed Vif-Vif association
within cells [33]. The domain mediating Vif self-association was first identified within
the C-terminal domain of the protein in the proline-rich 156-164 region [33]. More
precisely, the conserved 161PPLP164 domain in HIV-1 Vif protein (Fig. 2b) was shown
to play a key role in multimerization [35]. Vif multimerization at its C-terminus via
this motif is thought to release Pr55Gag, which binds to this region [35]. In HIV-1,
Vif mulimerization is crucial for viral infectivity [35] and for preventing APOBEC3G
incorporation into viral particles [36]. However, surprisingly, this multimerization
site is not conserved in HIV-2 or SIV (Fig. 1). Some regions of HIV-1 Vif are pre-
dicted to be intrinsically disordered (solid lines in Fig. 1). Indeed, large segments of
HIV-1 Vif secondary structure are predicted to be random coil (70-84, 130-143, 155-
192), with however a more ordered secondary structure predicted for the N-terminus
consisting of mostly β-sheets and one α-helix. Very recently, two models for the three-
dimensional structure of HIV-1 Vif were presented [37,38]. Briefly, both models are
based on predicted secondary structures shown in Fig. 1 and the search in the PDB
(Protein Data Bank http://www.rcsb.org/pdb/home/home.do) for protein 3D struc-
tures that shares the same secondary structures. The second model [38], which seems
to be more complete, incorporated the results of mutagenesis studies [39-41] that
indicate that Vif contains at least two functionally crucial domains: an N-terminal
domain that is important for binding to APOBEC3G, and a C-terminal region with a
conserved SLQ(Y/F)LAΦΦΦΦ motif similar to SOCS-box that is responsible for its
interaction with the ElonginB-ElonginC complex [13]. A three-dimensional model of
HIV-1 Vif was constructed by homology modelling using two templates: the SOCS-
box of VHL (von Hippel-Lindau tumor suppressor protein) as the template for the
C-terminal domain, and the N-terminal domain of Narl, whose secondary structure
presents strong similarity to the N-terminal domain of Vif [38]. While the two models
roughly present the same secondary structure of Vif, the three-dimensional foldings
are really divergent. The difficulties lie not only in organizing the secondary elements
with respect to each other to access the 3D-fold but also to model the large loops
present in Vif. Moreover, none of these models took into account the presence of the
HCCH domain that is also crucial for Vif activity and that could be determinant for
Vif folding. Each model can however provide specific details about mutation sites,
but they should be used with caution, because of lack of structural data such as X-ray
diffraction or NMR data.
III The N-Terminal Domain of VIF: Interaction with
APOBEC3F and APOBEC3G
Seven members of the APOBEC3 family (APOBEC3A–H) have been described in
primates with varying degrees of anti-viral activity, ranging from having no described
activity to potent inhibitory effects against retroviruses and retrotransposons (for a
review, see [10]). Binding of Vif to APOBEC3G/3F is essential for their degradation
by the Vif-Cullin5 E3 ligase [9,16,42] and a detailed knowledge of the interactions
between these two proteins is of great importance for the development of new drugs
aiming at blocking Vif-mediated degradation of APOBEC3G. In 2004, several in-
vestigators showed that the Vif-APOBEC3G interaction is species specific [43-46].
Indeed, human, chimpanzee, rhesus macaque (mac) and African green monkey (agm)
APOBEC3G proteins can inhibit ∆vif HIV-1, while only the human and chimpanzee
proteins are sensitive to HIV-1 Vif. Sequence analysis and mutagenesis showed that
amino acid 128 (D in human and K in mac and agm) in APOBEC3G was responsi-
ble for Vif sensitivity. However, while the interaction between Vif and APOBEC3G
was severely affected when amino acid 128 was mutated, it was not completely ab-
rogated [46] and surrounding amino acids such as P129 and D130 [47] and region
54-124 [48] have been shown to modulate the APOBEC3G-Vif interaction. Unlike
APOBEC3G, modification of amino acid 128 in human APOBEC3F did not change
its recognition by HIV-1 or SIVagm Vif [49]. It should also be pointed out that both
Vif and APOBEC3G are RNA-binding proteins [28,50] and that Vif-APOBEC3G
interactions could be mediated by RNA although a recent study showed that RNA
was not necessary for these proteins to interact [51].
Regarding the Vif protein, several lines of evidence suggested that the N-terminal
region contains the main binding sites for APOBEC3G and APOBEC3F (Fig. 2a)
[9,21,42,52- 57], while a short sequence encompassing amino acids 169– 192 in the
C-terminal has also been shown to mediate Vif- APOBEC3G interactions [53]. A pre-
vious study reported that single-amino-acid changes in Vif sequences isolated from
HIV-1-infected patients could be sufficient to prevent APOBEC3 neutralization [52].
Since then, a number of mutagenesis studies revealed that substitutions of highly con-
served residues in the N-terminus of Vif differentially affect the interactions of this
protein with APOBEC3G and APOBEC3F interactions [21,52,55-57]. For instance,
residues 85 to 99 [53] and 40YRHHY44 of Vif are important for binding to APOBEC3G
[56,57] whereas the 14DRMR17 residues are crucial for binding to APOBEC3F (Fig.
2a) [55,57]. A similar phenomenon was also observed with conserved tryptophan
residues located in the N-terminus of Vif: W11 and W79 are critical for interaction
with APOBEC3F while all other tryptophan residues (W5, W21, W38 and W89) are
important for Vif activity against APOBEC3G [21]. In addition to these residues,
other amino acids in Vif are likely to contribute to APOBEC3G or APOBEC3F
binding. It has been shown that I9 [54], K22, E45, and N48 [52,57] substitutions sup-
pressed Vif function against APOBEC3G but not APOBEC3F, but that Q12 [52,57]
reduced the ability of Vif to neutralize APOBEC3F. Taken together, these data sug-
gest that Vif contains nonlinear binding sites for APOBEC3G and APOBEC3F in
its N-terminus region (Fig. 2a) and that Vif- APOBEC3G interaction is depen-
dent on electrostatic interactions. Indeed, Schrofelbauer and co-workers [55] showed
that the defect of interaction between the D128K mutant of human APOBEC3G
and HIV-1 Vif could be compensated by substituting R15 and R17 residues by neu-
tral or negatively charged residues. These Vif mutants were also able to interact with
macAPOBEC3G and agmAPOBEC3G, which are naturally positively charged at po-
sition 128 (K). Moreover, the substitution of 14DRMR17 by SERQ, the exact amino
acid sequence found in agmVif, or by SEMQ, was sufficient to allow functional inter-
action of HIV-1 Vif with mac and agmAPOBEC3G, as well as human APOBEC3G
and D128K-APOBEC3G. Thus, the fact that region 14-17 of HIV-1 Vif removes the
species restriction imposed by residue 128 of APOBEC3G suggests a direct interac-
tion between these two regions. However, it does not rule out any conformational
rearrangement induced by mutations and the fact that the affinity between Vif and
APOBEC3G and APOBEC3F could be increased by additional interactions [21,55-
57].
IV HCCH Zn Binding Domain of VIF: a CULLIN5 Bind-
ing Domain
Vif hijacks the cellular Cullin5-Ring E3 ubiquitin ligase to degrade APOBEC3 pro-
teins (Fig. 3). Vif was shown to recruit Cullin5 in concert with ElonginB and C
and Rbx1 to form an E3 ubiquitin ligase complex [13,40,58] similar to ElonginB/C-
Cul2-SOCS-box complexes [59,60]. Vif proteins lack a clear Cullin5-box, and so the
molecular basis of the recruitment of Cullin5 was first unclear. The first residues
shown to interact with Cullin5 but not with ElonginB/C were the highly conserved
C114 and C133, upstream the SOCS-box [13] (Fig. 2a). Indeed, mutation of each
cysteine residue individually into a serine residue severely impaired the ability of
Vif to interact with Cullin5, but not with ElonginB/C. The two cysteine residues
were then shown to belong to a completely conserved HCCH motif with the sequence
H108-X5-C114-X18-C133-X5-H139 (Fig. 2b). The HCCH sequence and spacing are
highly conserved in Vif proteins and are critical for Vif function [61]. All individ-
ual residues of this HCCH motif were shown to be necessary for interaction with
Cullin5 [62]. Indeed, individual substitutions in each of the His or Cys abolished the
interaction with Cullin5 (in SIV-primate) leading the authors to the conclusion that
not only the two cysteines but also the two histidines contribute to the interaction
[62]. All conserved amino acids of this motif (between H108-H139) except G126 were
found to be critical for assembly of the Vif-Cullin5 E3 ubiquitin ligase [61]. This
HCCH motif was subsequently shown to form a structural domain that has the po-
tential to bind zinc, making Vif a zinc-binding protein [23,24]. This HCCH motif is
reminiscent of a zinc-finger like structure. However, the arrangement of the His and
Cys residues and the spacing between them in Vif appear to be unique when com-
pared to other known classes of zinc-binding domains [63]. Here again, it was shown
that each individual zinc-coordinating residue was essential for Cullin5 association
and APOBEC3G degradation but not for ElonginB/C binding [23,24]. Moreover, a
highly conserved stretch of hydrophobic residues F115-X4-I/V120-X2-A123-I/L124
(Figs. 1,2) within the Vif zinc-binding domain is required for the interaction with
Cullin5 [23]. F115 is present in most lentiviral Vif proteins, with W occasionally seen,
and F115A, I120S and AL123/124SS mutants lost the ability to interact with Cullin5
[23]. The hydrophobic motif within the zinc-binding domain of Vif forms a critical
functional interface with Cullin5. Disruption of this motif results in a defective Vif
that is unable to recruit Cullin5 and consequently has lost the ability to degrade
APOBEC3G [23]. Interestingly, it has been reported that HIV-1 Vif protein, as well
as a minimalist HCCH peptide mimicking the HCCH domain of Vif, changes its
conformation upon zinc binding [64]. Moreover zinc binding leads to rapid protein
aggregation that is efficiently reversed upon chelating agent treatment like EDTA
[64]. Zinc binding generates a conformation capable of forming high order protein
assemblies. This self-association property of Vif protein recalls the capacity of Vif to
form multimers, but it does not involve the same domain and the multimerization via
the PPLP domain lead up to tetramers and not to aggregation. The authors proposed
that zinc binding alters the native protein conformation to expose a protein-protein
interaction domain. The resulting conformation would display surface side chain
residues to the solvent, and could mediate protein-protein interaction, for example
with Cullin5 [64]. A recent study demonstrates that the arrangement of the zinc
coordination residues, HCCH, and the maintenance of both the conserved residues
and the spacing within the HCCH motif are critical for Vif function. Indeed deletion
of non conserved residues in each portion of the HCCH motif affected recruitment of
Cullin5, APOBEC3G degradation and viral infectivity [61]. It has also been shown
that chelation of zinc in cells by a membrane-permeable zinc chelator prevents Vif
function in infectivity assays, allowing the virus to become sensitive to the antiviral
activity of APOBEC3G [65]. To conclude, the HCCH zinc-binding motif facilitates
Vif-Cullin5 binding by playing a structural role in positioning hydrophobic residues
for direct contact with Cullin5.
V SOCS-BOX Domain of VIF: an ELONGIN B/C Bind-
ing Domain
It was known for a long time that substituting alanines for the 144SLQ149 Vif motif
causes a loss of HIV-1 infectivity [66]. The molecular explanation has been discov-
ered later [40], when this mutation was shown to affect formation of the Vif-Cullin5-
ElonginBC complex. Indeed, the ElonginBElonginC heterodimer is known to in-
teract with SOCS-box containing proteins [67,68]. Alignment of Vif proteins from
primate and non primate lentiviruses led to the recognition of a highly conserved
motif 144(S/T)LQ(F/Y/R)LA149 [20], homologous to a BC-box sequence conserved
in proteins that bind to ElonginB-ElonginC heterodimers [69]. More recently, the
conserved SLQ(Y/F)LAΦΦΦΦ motif of Vif was described to possess striking resem-
blance with the SOCSbox of SOCS proteins [13]. This putative SOCS-box of Vif
was then shown to mediate its interaction with ElonginC [13,58]. A major differ-
ence between the SOCS-box-like motif in HIV/SIV Vif and the consensus SOCS-box
motif [69] is the lack of a highly conserved C, replaced by A149 in Vif. This highly
conserved C is critical for interaction with ElonginC [67]. In Vif, both A and C at po-
sition 149 can mediate the interaction with ElonginC [13]. However, longer side chain
residues at this position, like L or T, prevent binding of ElonginC and degradation
of APOBEC3G [13].
Amino acids 145-155 are predicted to form an α-helix (Fig. 1). Using the crystal
structure of VHL-ElonginC [70] as a model, Yu et al. [13] have shown that L145,
A149, A152 and L153 of Vif could form a hydrophobic cluster with spacing similar
to hydrophobic residues of VHL. Importantly, these HIV-1 Vif hydrophobic residues
are predicted to be on the same face of the α-helix and could fit into the hydrophobic
pocket of ElonginC.
To sum up, the multidomain Vif protein recruits several cellular partners to
achieve the degradation of APOBEC3 proteins. Vif neutralizes the antiviral activity
of APOBEC-3G and APOBEC3F predominantly by forming an E3 ubiquitin ligase
with Cullin5, ElonginB and ElonginC that targets these proteins for degradation
by the ubiquitin-protea-some pathway. Vif associates with the Cullin5-ElonginB-
ElonginC complex by binding directly to ElonginC via its SOCS-Box motif and to
Cullin5 via hydrophobic residues within a zinc-binding region formed by a conserved
HCCH motif (Fig. 3). The HIV-1 Vif-Cullin5-ElonginBC complex is then able to
ubiquitinate the APOBEC3G factor bound to Vif by its N-terminal domain [71].
VI Interaction with the Genomic RNA
In infected cells, HIV-1 Vif co-localizes with the Pr55Gag precursor in membrane-free
cytoplasmic complexes that were proposed to be intermediate assembly complexes
[72]. On the other hand, Pr55Gag precursors associate with HIV-1 genomic RNA
(gRNA) at a perinuclear/centrosomal site [73]. In addition, it was shown that Vif
specifically binds HIV-1 gRNA in vitro, and that it binds this RNA in the cytoplasm of
virus producing cells to form a 40S mRNP complex that contains neither the Pr55Gag
precursor nor the mature nucleocapsid protein (NCp7) [26]. These results suggest that
the HIV-1 gRNA may be engaged in different complexes. However, the same authors
showed that in vitro, the affinity of Vif for the HIV-1 gRNA significantly decreased in
the presence of Pr55Gag, while the affinity of the latter protein for HIV-1 RNA was not
affected by Vif. Recently, we found that Vif preferentially and cooperatively binds to
the 5’ region of the HIV-1 gRNA, and that this region contains very high affinity Vif
binding sites [28,74]. Therefore, one can assume that some Vif proteins would remain
associated to the gRNA even in the presence of Gag. Indeed, by studying the cell-free
assembly of immature HIV-1 capsids, Lingappa and co-workers observed intermediate
assembly complexes containing the Gag and Gag-Pol precursors, as well as Vif and a
cellular factor, HP68, which is absolutely required to complete assembly [75]. In line
with these results, it has been reported that incorporation of Vif into viral particles
is mediated (at least in part) by interactions with the gRNA [27]. Interactions of Vif
with Gag and Gag-Pol likely also contribute to this process [76].
A strong affinity RNA binding site was identified in the N-terminal region of
Vif (amino acids 1-64), while the Cterminal region, which harbors many positively
charged residues, only weakly contributed to RNA binding [26]. Within the N-
terminal region of Vif, substitutions W11A, Y30A, and Y40A strongly reduced bind-
ing to both poly(G) and an RNA probe corresponding to nucleotides 5104 to 5287 of
the HIV-1 genome. In addition, viruses harboring any of these substitutions were non-
infectious in H9 T cells, suggesting that RNA binding is crucial for Vif function [26].
Moreover, viruses harboring mutations in the zinc finger domains of NCp7 that fail
to package gRNA do not package Vif, and Vif is not encapsidated in a HIV-1 RNA-
packaging mutant [27]. These authors also showed that deletions of the C-terminal
domain or of the viral SOCS-box had no effect on Vif packaging. Surprisingly in
light of the results of Zhang et al. mentioned above, Khan and co-workers found that
deletion of residues 23 to 43 increased the efficiency of Vif packaging twofold [27]. On
the other hand, deletion of amino acids 75 to 114 completely abolished packaging of
Vif. However, as this deletion encompasses part of the zincbinding motif (Fig. 2b),
this result may be the indirect consequence of a major conformational change of Vif
(see section IV).
The main HIV-1 RNA binding protein is the mature nucleocapsid protein NCp7
(and the NC domain embedded in the Gag precursor), which is a potent RNA chap-
erone (For reviews see [77,78]). Recent studies pointed at significant differences and
similarities between Vif and NCp7. Whereas the binding affinity of NCp7 for RNA
strongly decreases as the salt concentration increases [77,79], the Vif/RNA complexes
resist to high salt concentrations [26,28,74]. Indeed, at the physiological ionic con-
ditions, Vif binds stronger to gRNA than NCp7 [28,74]. NCp7 binds to any nucleic
acids with significant affinity, but it displays some preference for UG or TG-rich se-
quences and for GNG sequences within single stranded loops. The RNA and DNA
sites displaying the highest affinity for Vif are single-stranded G-rich and Crich se-
quences [74] and poly(G) is the homopolymer that binds Vif with the highest affinity
[26]. The determinants of specific binding of Vif to nucleic acids remain to be deter-
mined, but Vif binding seems to be more specific than NCp7 binding, as we identified
500 nucleotide RNA fragments that weakly bind Vif [28,74].
Interestingly, we recently found that Vif promotes annealing of tRNALys,3 to the
primer binding site (PBS), favors dimerization of the HIV-1 gRNA, decreases pausing
of reverse transcriptase and enhances the first strand transfer taking place during
reverse transcription, indicating that Vif is a bona fide RNA chaperone [80]. Even
though the chaperone activity of Vif is less pronounced than that of NCp7, Vif has
dominant effects on NCp7. Indeed, Vif inhibits some, but not all, NCp7-mediated
functions including tRNALys,3 annealing and conversion of the loose gRNA dimer
into a tight dimer [80]. These inhibitory effects of Vif are likely relieved at the last
stages of virion assembly, as only limited amounts of Vif are packaged [81-84], and
thus Vif could act as a temporal regulator of NCp7 activity. Recent reports indicated
that deamination is only one of the mechanisms contributing to the antiviral activity
of APOBEC3G and APOBEC3F. Some authors reported that these proteins also
inhibit NCp7- mediated tRNALys,3 annealing [85], and DNA strand transfers during
reverse transcription [86], while others observed an effect on DNA elongation [87].
These results may explain the need for redundant RNA chaperone activities in cells
expressing APOBEC3G and APOBEC3F.
CONCLUSIONS
In conclusion, Vif is a multidomain and multifunctional protein that therefore rep-
resent a viable target for both therapeutic and preventive interventions. However,
there are currently no drugs against this protein in clinical trials. To date, its func-
tion and structural features have been fairly well investigated. However, there still
exist numerous aspects that need to be resolved. A three-dimensional structure of
Vif, alone if Vif is not intrinsically disordered, or in complex with cellular partner(s)
would greatly help us to understand its behavior at the molecular level.
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Figure 1: Sequence Alignments of HIV/SIV Vif proteins
Highly conserved residues are on a dark blue background whereas residues with similar
physico-chemical characters are on a light blue background. The accession number of
each sequence in the Swiss-Prot database is indicated before its name. The predicted
secondary structure of the HIV-1 HXB2 Vif protein using the PSI-PRED program
[88] is shown below the sequences as arrows for β-strands and cylinder for α-helices.
Intrinsically disordered sequences are indicated by solid lines.
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Figure 2: The functional domains in HIV Vif
a) HIV-1 Vif contains several functional domains, including an APOBEC3F/G bind-
ing domain, a conserved zinc-binding hydrophobic HCCH motif and a downstream
SOCS-box. Conserved Tryptophans important for APOBEC binding are indicated as
well as Serine and Threonines that can be phosphorylated. b) Detailed architecture
of the HCCH domain, of the multimerization domain and of the SOCS-box encom-
passing the viral BC-box 144SLQYLA149 plus 4 hydrophobic residues of HIV-1 Vif















Figure 3: Function of Vif
Vif specifically recruits APOBEC3G into a Cullin5 E3-ligase complex for ubiqui-
tination and subsequent proteasome degradation. Vif associates with the Cullin5-
ElonginB-ElonginC complex by binding directly to ElonginC via its SOCSbox motif
and to Cullin5 via hydrophobic residues within a zinc-binding region formed by a
conserved HCCH motif. The HIV-1 Vif-Cullin5-ElonginBC complex is then able to
ubiquitinate the APOBEC3G factor bound to Vif by its N-terminal domain.
